About 800 national and international first -level experts have met these days to discuss the main challenges and advances in prevention and treatments within the framework of the II Congress of Obesity and Metabolic Complications.
The meeting, held in Seville, is organized jointly by the Spanish Society for the study of obesity (SEEDO), the Spanish Society of Morbid disease and metabolic diseases (dry) and the obesity section ofThe Spanish Association against Cancer (AEC).
The LPG-1 intestinal hormone alters the brain response to food by increasing the satiating effect.
Specialists insist on the importance of considering obesity a chronic disease whose causes are multifactorial, with a great impact on health and the way of life and with a high economic cost.
Diabetes is one of the main metabolic complications of obesity, in fact, 80% of cases of this type 2 disease are associated with obesity.In this regard, pharmacological treatments directed to new therapeutic targets for the treatment of obesity such as the LPG-1 intestinal hormone that alters the brain response to food by increasing the satiating effect.
new dietary strategies
The new dietary strategies for the approach to obesity have opened the debates in this forum, where Dr. Felipe Casanueva has presented the results of a recent study in which the effect of protein diets on body composition and body composition was analyzed for the first timeMuscle strength
“In the descent of weight it is very importantMetabolic expenditure of the patient, ”explains Dr. Casanueva.
In this sense, it is estimated that in the reduction of weight achieved by hypocaloric diet, 75% of the lost weight corresponds to fatty tissue and 25% to lean tissue.In view of the results, the question of whether the hypocaloric diet must continue to be considered the best option to lose weight and effectively fight against obesity.
In the first sessions of this meeting, other aspects such as surgery and bariatric endoscopic therapies have also been addressed;Metabolic surgery in the treatment of type 2 diabetes;or the pharmacological treatments aimed at new therapeutic targets for the treatment of obesity.
